Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT02916147Unknown
Randomised trial of sevoflurane in non-small cell lung carcinoma (NSCLC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoints: high mobility group nucleosome-binding protein-1 at 2 days and high mobility group proteins b1 at 2 days. Status: unknown.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT02916147.